COBIMETINIB (TARGETED THERAPY) PLUS ATEZOLIZUMAB (IMMUNOTHERAPY) IN PARTICIPANTS WITH ADVANCED MELANOMA WHOSE CANCER HAS WORSENED DURING OR AFTER TREATMENT WITH PREVIOUS IMMUNOTHERAPY AND ATEZOLIZUMAB MONOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA: